Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Girard

Showing results (51-60 of 113) with videos related to

Pageof 12
Sort By:
Annals of Neurology|December 30, 2014
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisTomas Kalincik, Dana Horakova, Tim Spelman, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Plos One|July 7, 2012
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeClaire Meyniel, Timothy Spelman, Vilija G Jokubaitis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 30, 2011
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase RegistryStella Hughes, Timothy Spelman, Maria Trojano, et al.
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 7, 2014
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, et al.
The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.
Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.
Pageof 12

Showing results (51-60 of 113) with videos related to

Sort By:
Pageof 12
Annals of Neurology|December 30, 2014
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisTomas Kalincik, Dana Horakova, Tim Spelman, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Plos One|July 7, 2012
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeClaire Meyniel, Timothy Spelman, Vilija G Jokubaitis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 30, 2011
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase RegistryStella Hughes, Timothy Spelman, Maria Trojano, et al.
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 7, 2014
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, et al.
The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.
Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.
Pageof 12